The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Good move PL75
@Rorydinho, well all I can say is I hope the Avacta managment are as wise and clever as you.😂😂😅
TookacarinLiverpool has added art to Novis? Wonders will never cease.
Fantastic news for Avacta Therapeutics inc you complete c*ck.
If ANYONE hasn't twigged it yet, just filter this computer-generated bot twat and its imbecilic drivel.
@Rorydinho: I'm not sure what you mean by "Avacta taking Precision to market." I suppose you mean pre|CISION, which is the name of the technology platform, but no one will be taking that to market so I suppose you really mean AVA6000. Hands up who thinks Avacta will be taking AVA6000 all the way to market. ...Anyone?
Additionally, re: "There’s a considerably larger risk premium here than previously due to management and the company’s finances." It all depends whether the NEW management can repair the company's finances with a revenue-generating deal or two. The clinical development of AVA6000 and the proving of the pre|CISION platform will progress this year (it DOES work - does the market realise that?) so deals are more likely. Has the market factored that possibility/probability in? The market got it very wrong last year on the over-optimistic side. Who's to say which way the market will get it wrong this year.
Big market for hair restoration. Could even be the kudos of a royal appointment.
Applicants are Epibiotech Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Apicell Therapeutics Co., Ltd.
For those who weren't aware, Apicell is AffyXell through a translation engine.
Patent details: https://patents.google.com/patent/WO2024054006A1/en?oq=WO2024054006
Epibiotech is a Korean company focussed on hair loss. 🤔Interested.
Yeah, but lemmings don't build planes.
Thank you JT. That'll be it.
From yesterday's RNS: "[18F]FAPI-74 PET is currently in clinical development and for investigational use only."
Can someone explain how [18F]FAPI-74 is used differently as a diagnostic and as a therapeutic? Wouldn't its use as a diagnostic also have at least some potential therapeutic effect?
Because some tumour have high levels of FAP, some have mid levels, and some have low levels.
Now how else would you determine what level of FAP a particular peson with a particular cancer has?
Classic! GeneralOz, what a comedian!!! Thanks for the chuckle. You and Thorn. To me, to you, to me, to you.😂😂😂
That also answers any questions about how the selected patients for FAPI-PET are to be selected.
But can an organisation dictate the placing price and demand changes to the BoD as requirements before buying in and owning less than 3% of a company?
Besides, from the NVF website:
"The Novartis Venture Fund team’s approach to investing
"We prefer an active, hands-on style of investment, one major element of which involves taking a seat on the company board. This enables us to collaborate closely with leadership and management."
I think they mainly do this with companies that are much smaller and earlier stage than Avacta, or they used to (from personal experience), or after taking a greater than 3% stake in a larger and more developed company. Venture funds are, after all, essentially incubators.
CTSFO asks "why now?" Well, we don't know how long this has been in the planning. I'd rather we be surprised by something like this than to have the possibility dangled and then it coming to nothing or being endlessly in the process of being implemented - you know how impatient our FUDsters are.
And what does it add? Well, AS was constantly working off that old table of FAP concentrations. And it was old and quite limited. This scanning technique will offer very precise results. Maybe they've found that the data in that table aren't reliable predictors. Maybe they've found discreprencies in the clinical responses (an after-the-event surrogate for FAP levels) between patients for the same cancer. Maybe they want to home in on the STS sub-types that will give good clinical responses in the registrational trial. Maybe all or these and more reasons.
Absolutely desperate FUDding there from one of the resident trolls that, unfortunately for it, knows nothing and therefore just makes a twat of itself. Probably never listened to when AS explained why FAPI-PET was difficult to implement. Probably? Definitely, as never listens to anything.
All that but no TR1?
@TheTruth23's "No mention of FDA approval timelines etc? Be great, as others have suggested, if they could properly map out where they are and a detailed steps plan for the next months and years."
Don't be ridiculous. A detailed steps plan for the next years? Oh I see, you are simple AND ridiculous.🤣🤣🤣
Good news! - and nice mix of British English and American English, although tumour has definitely become tumor.
Very pleased that we've moved past the end of A2C1 and not only actually started A2C2 but also a study to identify high FAP cancers, and specifically cancer subtypes, on an at least individual person basis.
Avacta could never have fitted four cohorts of 8 weeks into the timeline stated since the first time this arm was mooted, and especially not since the 28 February fundraise announcement, even using Alan's magic calendar.